


What is claimed is:

1. A compound according to formula (I) below, having the structure:




Formula (I)

- 5 wherein:


R^1 is selected from the group consisting of hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkanoyl and aroyl;

G^1 represents CH_2-CH_2 or $CH=CH$;

G^2 represents C_{4-7} alkyl or a group of the formula (a), (b) or (c):



X represents a group of the formula (d) or (e):



- 15 wherein

Y is selected from the group consisting of a bond, OR^2 , SR^2 , NR^2R^3 , and C_{1-4} alkyl;

R^2 represents a bond or C_{1-4} alkyl;

R^3 represents a hydrogen or C_{1-4} alkyl;

- 20 Ar represents an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring;

L represents a bond, C_{1-4} alkyl or C_{3-8} cycloalkyl;

2. A compound according to claim 1 selected from the group consisting of:

N-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-2-[2-({4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexylcarbamoyl}-methyl)-phenyl]-acetamide;

- 5 N-{4-[2-(1,2,3,4-Tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-3-[2-({4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl-carbamoyl}-methyl)-phenyl]-acetamide.

3. A method of antagonizing the M₃ muscarinic acetylcholine receptor by administering to a subject in need thereof a safe and effective amount of a
10 compound according to claim 1.
4. A method of treating a disease or disorder selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis, irritable bowel syndrome, spasmodic colitis, gastroduodenal ulcers, gastrointestinal
15 convulsions or hyperanalkinesia, diverticulitis, pain accompanying spasms of gastrointestinal smooth musculature; urinary-tract disorders accompanying micturition disorders, neurogenic pollakisuria, neurogenic bladder, nocturnal enuresis, psychosomatic bladder, incontinence associated with bladder spasms or chronic cystitis, urinary urgency or pollakiuria, and motion sickness.
- 20 5. A pharmaceutical formulation comprising an active according to claim 1 and a suitable carrier.
6. A container containing a pharmaceutical formulation according to claim 1 fitted with a metering valve.
7. A device adapted for intranasal delivery of a pharmaceutical formulation
25 comprising a container according to claim 6.